The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IVVD | +98.88% | N/A | N/A | -92% |
| S&P | +12.57% | +87.93% | +13.44% | +52% |
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
The clinical-stage biotech delivered positive trial results for its new COVID-19 preventative antibody treatment.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $13.13M | 41.2% |
| Gross Profit | $11.61M | 46.3% |
| Gross Margin | 88.43% | 3.1% |
| Market Cap | $214.45M | 76.0% |
| Market Cap / Employee | $2.17M | 0.0% |
| Employees | 99 | 5.3% |
| Net Income | -$10.47M | 82.8% |
| EBITDA | -$10.59M | 82.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $84.97M | -20.5% |
| Accounts Receivable | $9.85M | 20.8% |
| Inventory | 0.4 | -98.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.59M | 627.9% |
| Short Term Debt | $1.08M | -23.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -39.76% | 63.3% |
| Return On Invested Capital | -106.74% | -36.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$8.25M | 79.9% |
| Operating Free Cash Flow | -$8.25M | 79.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.64 | 1.07 | 1.58 | 3.09 | 256.57% |
| Price to Sales | 2.09 | 1.98 | 1.86 | 3.74 | -64.51% |
| Price to Tangible Book Value | 0.64 | 1.07 | 1.58 | 3.09 | 256.53% |
| Enterprise Value to EBITDA | 0.84 | -1.57 | -3.70 | -9.90 | 3573.23% |
| Return on Equity | -138.7% | -122.7% | -120.1% | -67.9% | -50.26% |
| Total Debt | $1.30M | $0.89M | $2.97M | $2.68M | 63.93% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
